InMed Pharmaceuticals amended exercise prices of preferred investment options with Sabby and Wainwright affiliates from $2.436 and higher to $0.80 per share.
Key takeaways
Sabby's exercise price reduced from $2.436 to $0.80 per share for up to 2,151,478 common shares.
Wainwright affiliates' exercise prices reduced to $0.80 per share for up to 153,236 common shares.
Amendments were made on April 21 and April 24, 2026, respectively.
The options were originally issued in private placements under Section 4(a)(2) and Regulation D.
No assurance is given that any of the options will be exercised.